STRATEGY
We intend to bring our products to market using the following business strategies:
- Develop Oral Antibody Therapies for Significant Unmet Medical Needs
By focusing our oral antibody technology on disease targets accessible via the GI tract, we believe we can create important new therapeutic products within a unique and defensible market space. - Utilize Bovine Polyclonal Antibodies for Rapid and Low Cost Development
While we have potential IP on methods to engineer monoclonal antibodies for oral delivery, we believe that our bovine polyclonal technology platform offers compelling advantages in product cost and safety as well as in the time and cost of clinical development. - Implement a Flexible, Capital-Efficient Plan Using a Semi-Virtual Business Model
Around a small team of experienced management, we have built an extensive virtual organization. This approach enables us to harness a wide range of capabilities while keeping our overhead and fixed expenses very low. - Advance Products Through Early Clinical Trials
We believe we can achieve compelling returns for our investors by demonstrating the breadth and value of our technology platform and products in preclinical research and Phase II trials.
